Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The alloreactive immune response is the adaptive (and sometimes innate) immunological reaction to foreign antigens within the same species (alloantigens), such such as mismatched HLA or blood antigens. It is primarily mediated by alloreactive T cells recognizing non-self MHC molecules through direct, indirect, or semi-direct allorecognition pathways, with roles for B cells (alloantibody production) and other immune effectors. This response is the main cause of transplant rejection, graft-versus-host disease, transfusion reactions, and certain maternal-fetal incompatibilities. Interventions to modulate alloreactivity form the foundation of clinical transplantation immunology. This entry refers to an immune response/process, not a discrete molecular or cellular therapeutic target such as a receptor, enzyme, or transporter.
Immunosuppression targeting T cells and/or B cells to prevent or reduce alloreactivity (e.g., via calcineurin inhibition, DNA alkylation, lymphocyte depletion). Treg-based tolerance induction.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alloreactive immune response.